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Transcriptional regulation of genes by cyclic AMP response element binding protein (CREB) is essential for the
maintenance of long-term memory. Moreover, retrograde axonal trafficking of CREB in response to nerve growth
factor (NGF) is critical for the survival of developing primary sensory neurons. We have previously demonstrated that
hindpaw injection of interleukin-6 (IL-6) induces mechanical hypersensitivity and hyperalgesic priming that is
prevented by the local injection of protein synthesis inhibitors. However, proteins that are locally synthesized that
might lead to this effect have not been identified. We hypothesized that retrograde axonal trafficking of nascently
synthesized CREB might link local, activity-dependent translation to nociceptive plasticity. To test this hypothesis,
we determined if IL-6 enhances the expression of CREB and if it subsequently undergoes retrograde axonal
transport. IL-6 treatment of sensory neurons in vitro caused an increase in CREB protein and in vivo treatment
evoked an increase in CREB in the sciatic nerve consistent with retrograde transport. Importantly, co-injection of IL-6
with the methionine analogue azido-homoalanine (AHA), to assess nascently synthesized proteins, revealed an
increase in CREB containing AHA in the sciatic nerve 2 hrs post injection, indicating retrograde transport of
nascently synthesized CREB. Behaviorally, blockade of retrograde transport by disruption of microtubules or inhibition
of dynein or intrathecal injection of cAMP response element (CRE) consensus sequence DNA oligonucleotides, which
act as decoys for CREB DNA binding, prevented the development of IL-6-induced mechanical hypersensitivity and
hyperalgesic priming. Consistent with previous studies in inflammatory models, intraplantar IL-6 enhanced the
expression of BDNF in dorsal root ganglion (DRG). This effect was blocked by inhibition of retrograde axonal transport
and by intrathecal CRE oligonucleotides. Collectively, these findings point to a novel mechanism of axonal translation
and retrograde trafficking linking locally-generated signals to long-term nociceptive sensitization.Background
Nociception, including nociceptive plasticity that fre-
quently accompanies injury, serves a vital physiological
function in vertebrates and invertebrates with complex
nervous systems. It prompts an escape response from a
source of real or potential tissue damage and plasticity
in the nociceptive system guards against further damage
by promoting a protective response during healing
which is crucial for recuperation and survival [1].
However, these same plasticity mechanisms can lead to* Correspondence: Theodore.price@utdallas.edu
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article, unless otherwise stated.exaggerated nociceptive sensitization or a failure of
resolution of hypersensitivity after tissue healing has
completed its course, both of which may contribute to the
development of chronic pain states [2]. The elucidation of
molecular mechanisms that promote injury-induced noci-
ceptive plasticity can provide insight into the development
and possibly maintenance of chronic pain states [3]. Mo-
lecular mechanisms that are conserved across the animal
kingdom may have particular salience for understanding
how and why pain becomes chronic.
A potential, highly conserved mechanism of nociceptive
plasticity is local translation of new proteins in response
to injury [4-7]. In aplysia, crush injury to sensory neuron
axons creates a sustained hyperexcitability in those sameentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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transplantation of axoplasm from the site of an injured
aplysia axon to an uninjured one creates a state of en-
hanced excitability matching that produced by injury.
Interestingly, this appears to involve a local change in a
protein that then undergoes retrograde transport po-
tentially leading to a phenotypic change in the axon
based on a transcriptional change [8]. Although the
identity of the protein involved in this local change has
not been formally elucidated, the time course of the
effect is consistent with a locally translated protein.
We, and others, have provided compelling evidence for
local translation as an important feature in the sensi-
tivity of mammalian nociceptors and their plasticity in
response to injury [4-7]. Here the mechanistic target of
rapamycin complex 1 (mTORC1) and extracellular signal
regulated kinase (ERK)/eukaryotic initiation factor 4E
(eIF4E) signaling pathways play a key role linking ex-
tracellular inflammatory factors to local changes in gene
expression in nociceptor axons at the level of translation
[6,9,10]. Having said this, proteins that are synthesized
locally in response to factors that promote pain plasticity
have not been identified.
“Hyperalgesic priming” models use an initial insult to
produce plasticity in the nociceptive system that mani-
fests as an enhanced propensity to a long-lasting pain
state with a subsequent, normally sub-threshold, stimu-
lus. Hyperalgesic priming serves as an important model
for investigation of pain plasticity mechanisms because it
provides a clear experimental platform for the investigation
of mechanisms involved in the transition to a chronic pain
state [2,11,12]. For instance, in mice and rats a single injec-
tion of interleukin-6 (IL-6) causes a transient mechanical
hypersensitivity that resolves within 3 days. Importantly,
in these primed animals, after they no longer show an
overt nociceptive hypersensitivity, a normally sub-threshold
injection of prostaglandin E2 (PGE2) causes a long lasting
reinstatement of mechanical hypersensitivity [6,12,13]. The
initiation of this priming event is blocked by inhibition of
translation at the site of the primary insult [6] or, during
the maintenance phase, by sequestration of spinal brain
derived neurotropic factor (BDNF) [14] providing a pos-
sible link between changes in local gene expression
within the paw and longer-term alterations in BDNF ex-
pression in dorsal root ganglion (DRG) neurons. This
notion is consistent with findings in invertebrate axons
in response to injury [4,8] potentially pointing to a con-
served role for local translation of retrograde signaling
factors in nociceptive plasticity. A candidate for this
nascently synthesized retrograde signaling molecule is
the transcription factor cAMP-responsive element (CRE)-
binding protein (CREB). Significantly, CREB has been iden-
tified as a nascently synthesized protein within the axons
of developing DRG neurons in response to nerve growthfactor (NGF) where it is then retrogradely transported
to the nucleus to regulate gene expression critical for
the early survival of these neurons [15]. Based on this, we
hypothesized that IL-6-mediated mechanical hypersensi-
tivity and hyperalgesic priming may be dependent on the
local synthesis and retrograde trafficking of CREB.
In this study we provide evidence that CREB is locally
translated in response to intraplantar administration of
IL-6. Furthermore, we detail observations consistent
with retrograde transport of this nascently synthesized
CREB linking local changes in gene expression on the
level of translation to enhanced BDNF expression in DRG
neurons. Our findings provide evidence for a conserved
mechanism of nociceptive plasticity.
Results
IL-6 induces the expression of CREB in vivo and in vitro
The transcription factor CREB is synthesized within axons
of developing DRG neurons in an NGF-dependent fashion
and transported back to the neuronal nucleus where it
influences transcription of genes regulating the survival
of DRG neurons [15]. Local translation plays a key role in
the sensitization of mammalian nociceptors, and is in-
volved in the initiation and maintenance of hyperalgesic
priming. Local translation is likewise linked to hypersensi-
tivity arising in invertebrate sensory neurons after crush
injury. We therefore hypothesized that local translation of
CREB may link local translation of a transcription factor
to IL-6-induced nociceptive plasticity. We have previously
demonstrated that IL-6 activates the ERK/eIF4E pathway
leading to enhanced translation of proteins in the axons of
primary sensory neurons. Moreover, IL-6 induced mechan-
ical hypersensitivity and subsequent PGE2-induced precipi-
tation of hyperalgesic priming is blocked by inhibition of
translation at the site of IL-6 injection [6]. As a first test of
our hypothesis we asked if IL-6 induces a rapid change in
CREB expression in DRG neurons. Treatment of DRG neu-
rons in culture with IL-6 (50 ng/mL) for 15 minutes caused
increased expression of CREB (Figure 1A) consistent with
the time and concentration dependent activation of ERK
and eIF4E phosphorylation we have determined previously.
This finding suggests that DRG neurons can synthesize
CREB in response to IL-6. In order to determine if an
IL-6-mediated synthesis of CREB in DRG neurons can
lead to retrograde transport, we injected IL-6 (0.1 ng) or
vehicle into the paws of mice and collected the sciatic
nerves at 15 min (a time point too rapid for retrograde
transport) or 2 hrs (a time point where maximal retro-
grade transport would be predicted based on standard
retrograde transport rates and the distance from the paw
where the sciatic nerve was removed) later. As expected,
at 15 min post injection, IL-6 did not induce an increase
in the levels of CREB within the sciatic nerve (Figure 1B).
However, 2 hrs following i.pl. injection of IL-6 we observed
Figure 1 IL-6 induces CREB synthesis in vitro and in vivo. A)
Western blot and quantification of CREB following 15 min treatment of
DRG cultures with escalating concentrations of IL-6. N = 8 independent
culture wells per condition. B) Western blot and quantification of CREB
in the ipsilateral sciatic nerve following intraplantar (IPL) injection of
IL-6 (0.1 ng) or vehicle. CREB protein is enhanced in the sciatic nerve
2 hrs post-injection but not at 15 min following treatment. N = 6 mice
per condition. C) Western blot and quantification for nascently
synthesized CREB retrogradely transported to the sciatic nerve.
Retrograde axonal trafficking of nascently synthesized CREB was
determined by co-injecting IL-6 (0.1 ng) or vehicle with the methionine
analogue AHA into the paw and measuring, from the sciatic nerve, the
amount of CREB with incorporated AHA, 2 hrs post injection. The
input lane contains lysate from sciatic nerve that did not undergo
immunoprecipitation and is labeled with biotin-avidin on incorporated
AHA. N = 6 mice per condition. * = p < 0.05 and ** = p < 0.01.
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(Figure 1B). These data suggest that locally synthesized
CREB in the axons of DRG neurons in the paws of mice
that were treated with IL-6 undergo retrograde transport
into to the sciatic nerve. We next sought to demonstrate
that this IL-6-induced CREB translocation to the sciatic
nerve was nascently synthesized at the site of IL-6 injec-
tion. To this end we co-injected IL-6 with the methionine
analogue AHA along with vehicle or IL-6 and sciatic
nerves were dissected after 2 hrs. In order to detect AHA
incorporation into nascently synthesized CREB we immu-
noprecipitated CREB and used “click chemistry” to label
AHA with biotin, which was subsequently detected by
Western blotting. Using this method, we observed an IL-
6-dependent increase in nascently synthesized CREB in
the sciatic nerve 2 hrs following treatment (Figure 1C).
Collectively, these data provide evidence that IL-6 stim-
ulates the local translation of CREB in axons of DRG
neurons, which then undergoes retrograde transport
into the sciatic nerve.
Axonal retrograde transport is critical for the initiation
and maintenance of IL-6-mediated hyperalgesic priming
Our hypothesis posits that translation links local signaling
events to long-term changes in nociceptors via retrograde
transport of a locally synthesized transcription factor.
Hence, we next sought to determine the role of retrograde
axonal transport in the development and maintenance of
hyperalgesic priming. To this end, we used colchicine and
nocodazole, which disrupt the polymerization of tubulin
monomers to form microtubules, therefore inhibiting fast
axonal anterograde and retrograde transport. We coupled
the intraplantar injection IL-6 with the injection of vehicle,
colchicine (100 μg) or nocodazole (10 μg) [8] in the poplit-
eal fossa of mice. The popliteal fossa is next to the sciatic
nerve and can provide a reservoir for drug to bathe the
sciatic nerve following appropriate injection. Injection
of vehicle into the popliteal fossa had no effect on the
initiation or maintenance of IL-6 induced hyperalgesic
priming (Figure 2A). However, popliteal fossa injection of
either colchicine or nocodazole prevented IL-6-mediated
mechanical hypersensitivity and hyperalgesic priming
to subsequent PGE2 treatment (Figure 2A). In order to
provide a more direct link to retrograde axonal trans-
port as a critical mediator of IL-6-mediated mechanical
hypersensitivity and hyperalgesic priming we used a
selective inhibitor for cytoplasmic dynein, ciliobrevin
D. Ciliobrevin D blocks dynein-dependent microtubule
gliding and ATPase activity while sparing kinesin
dependent cellular trafficking therefore selectively affecting
retrograde transport [16]. Popliteal fossa injection of cilio-
brevin D (10 μg) prevented both IL-6-induced mechanical
hypersensitivity and hyperalgesic priming (Figure 2B). To
assess whether the effects of nocodozole or ciliobrevin D
Figure 2 Disruption of axonal trafficking in the sciatic nerve prevents IL-6-mediated nociceptive plasticity. A) Disruption of microtubules
with the injection of colchicine (100 μg) or nocodazole (10 μg) into the popliteal fossa (PF) of mice prevented the development of mechanical
hypersensitivity and hyperalgesic priming caused by intraplantar injection of IL-6 (0.1 ng). N = 6 mice per condition. B) Popliteal fossa injection of
the cytoplasmic dynein inhibitor ciliobrevin D (10 μg) prevented the development of mechanical hypersensitivity and hyperalgesic priming
caused by Intraplantar injection of IL-6 (0.1 ng). N = 6 mice per condition. C) Right popliteal fossa injection of ciliobrevin D or nocodazole
(both at 10 μg) fails to disrupt the effect of IL-6 given into the left hindpaw. N = 6 mice per condition D) Popliteal fossa injection of ciliobrevin D
(CBD, 10 μg) at the time of intraplantar injection of IL6 prevented the enhancement of BDNF expression in the L4-L6 DRGs of mice 3 hrs following
injections. N = 6 mice per condition. * = p < 0.05 and *** = p < 0.001.
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compounds into the contralateral popliteal fossa at the
same dose at the time of IL-6 injection. As opposed to ipsi-
lateral injections, neither compound had an effect on IL-6-
induced mechanical hypersensitivity at any time point when
given contralaterally (Figure 2C). These results strongly
suggest that retrograde axonal transport is necessary for
IL-6-mediated nociceptive plasticity.
IL-6-mediated changes in DRG BDNF expression are
linked to retrograde CREB signaling
BDNF is released by nociceptors in response to noxious
stimulation and has a profound effect on post-synaptic
dorsal horn neurons. BDNF expression shows remarkable
plasticity in the DRG following inflammation and BDNF
expression in nociceptors is critical for inflammatory injury
induced nociceptive plasticity. We have recently shown
that IL-6-induced mechanical hypersensitivity and hyper-
algesic priming are dependent on BDNF/trkB signaling
[14]. Interestingly, IL-6-induced hyperalgesic priming can
be disrupted at any time by blocking BDNF/trkB signaling
suggesting that IL-6 mediated priming fundamentally
changes BDNF/trkB signaling between DRG and dorsal
horn neurons. How is this regulated? CREB is known to
regulate the expression of BDNF in neurons [17], there-
fore, we determined whether expression of BDNF is in-
creased following i.pl. injection of IL-6 and whether theblockade of retrograde axonal transport would prevent
this effect. We again used popliteal fossa injections of
ciliobrevin D at the time of i.pl. injections of IL-6 and mea-
sured the expression of BDNF in the dorsal root ganglia
3 hours post-injection (a time point at which CREB retro-
gradely transported from the paw should reach the DRG).
We determined that intraplantar injection of IL-6 enhanced
the expression of BDNF in the L4-L6 DRG and that this
effect was blocked by popliteal fossa injection of ciliobrevin
D (Figure 2D). These results link retrograde axonal trans-
port in the sciatic nerve to IL-6-mediated changes in BDNF
expression in the DRG, however the experiment cannot
specify CREB as a regulator for the IL-6-mediated effects.
To address this, we took advantage of CREB binding to
cAMP response element (CRE) consensus sequences in
DNA, an event normally linked to CREB’s action as a
transcription factor. To disrupt the binding of CREB to
CREs we administered intrathecal DNA decoy oligonucle-
otides that contain either the CRE consensus or mutant
sequence [18-20]. The decoy CRE consensus oligonucleo-
tides prevented the development of i.pl. IL-6-mediated
mechanical hypersensitivity and hyperalgesic priming
whereas CRE mutant oligonucleotides were without effect
(Figure 3A). Moreover, i.t. administration of the CRE
consensus decoy oligonucleotides, but not mutant oligo-
nucleotides, prevented IL-6-mediated increases in BDNF
expression in DRG 3 hrs after IL-6 treament (Figure 3B).
Figure 3 Disruption of CREB action in the DRG attenuates IL-6-induced nociceptive plasticity. A) Intrathecal injection of cAMP response
element (CRE) consensus sequence DNA oligonucleotides at the same time as intraplantar IL-6, prevented the development of IL-6-induced
mechanical hypersensitivity and hyperalgesic priming. Mutant CRE oligos were not effective. N = 6 mice per condition. B) Intrathecal injection of
CRE consensus sequence DNA oligonucleotide (CRE con) at the same time as intraplantar IL-6, prevented enhancement of BDNF expression in
L4-L6 DRGs 3 hours following injections. N = 6 mice per condition. C) Intrathecal injection of BDNF (0.1 ng) mechanical hypersensitivity and
hyperalgesic priming. Co-injection of CRE consensus sequence DNA oligonucleotides with BDNF did not affect mechanical hypersensitivity and
hyperalgesic priming. N = 6 mice per condition. * = p < 0.05, ** = p < 0.01 and *** = p < 0.001.
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of BNDF in the DRG and IL-6-induced mechanical
hypersensitivity and hyperalgesic priming to the retrograde
transport of CREB.
Nociceptive plasticity in the dorsal horn is regulated
by numerous transcription factors which include CREB
[21,22]. A possible interpretation of the CRE decoy oligo-
nucleotide experiment is blockade of CREB action in dorsal
horn neurons. Thus, we aimed to demonstrate that CREB
acts upstream of BDNF in DRG neurons. To this end, we
co-injected i.t. BDNF, at a dose we previously determined
to induce mechanical hypersensitivity and hyperalgesic
priming of a similar duration and magnitude to IL-6,
with and without CRE consensus decoy oligonucleotides.
Unlike experiments where IL-6 was injected into the
paw, CRE consensus oligonucleotides failed to alter i.t.BDNF-induced mechanical hypersensitivity or hyperalgesic
priming (Figure 3C). Therefore, we conclude that CREB
acts upstream of BDNF in the DRG and that CREB is not a
key mediator of BDNF-induced nociceptive plasticity in the
dorsal horn, at least over this time course.
Finally we asked whether the effects of ciliobrevin
D might be mediated by effects on nerve conduction.
Because IL-6-induced mechanical hypersensitivity develops
slowly and there is no acute response to IL-6 we turned
to capsaicin in these experiments. Mice received popliteal
fossa injections of vehicle, lidocaine (2%) or ciliobrevin D
(10 μg) and i.pl. injections of 0.9% capsaicin 5-10 min
later. While robust nocifensive responses to capsaicin
were observed in the vehicle and ciliobrevin D treated
mice, lidocaine, as expected, completely blocked this effect
(Figure 4A). We then measured mechanical hypersensitivity
Figure 4 Popliteal fossa injection of ciliobrevin D does not
influence capsaicin-induced flinching but does affect late
mechanical hypersensitivity. A) Popliteal fossa injection of vehicle
or ciliobrevin D had no effect on capsaicin (0.9%)-induced nocifensive
behaviors whereas lidocaine injection completely blocked the effects
of capsaicin. N = 4 - 5 mice per condition. B) Lidocaine completely
blocked capsaicin-induced mechanical hypersensitivity whereas
ciliobrevin D only had an effect at 3 hrs after capsaicin injection.
N = 4 – 5 mice per condition. * = p < 0.05 and *** = p < 0.001.
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At 1 hr, mechanical hypersensitivity was observed in the
vehicle and ciliobrevin D groups but at 3 hrs there was
an attenuation of mechanical hypersensitivity in the
ciliobrevin D group compared to vehicle (Figure 4B).
Mechanical hypersensitivity was completely blocked by
lidocaine injection (Figure 4B). These results are con-
sistent with the time course of retrograde transport in
IL-6 experiments with ciliobrevin D and demonstrate
that ciliobrevin D has no effect on acute pain-related
behaviors or mechanical hypersensitivity.Discussion
CREB is a major transcription factor that mediates activity-
dependent gene transcription across a wide variety of cell
types [23]. CREB is a crucial component of transcriptional
enhancers that regulate functions of the developing
and mature brain, including in neuronal survival, syn-
aptogenesis, synaptic plasticity and drug addiction
[22,24-26]. CREB has also been demonstrated to be crucial
for the development of mechanical and thermal hypersen-
sitivity in a variety of preclinical pain models [27-31].
However, post-translational mechanisms of CREB regula-
tion (e.g. phosphorylation) or CREB DNA targets have been
the focus of those studies [27,32-36]. Our current results
add a new layer of evidence to the role of CREB in nocicep-
tive plasticity and uncover a new mechanism for the devel-
opment of chronic pain – local translation and retrograde
transport of a transcription factor.
Our findings support a model wherein IL-6-mediated
mechanical sensitization is mediated by the local transla-
tion of CREB, its retrograde transport and subsequent
induction of BDNF expression in the DRG. Evidence for
this model is three pronged. 1) IL-6 treatment leads to
nascent synthesis of CREB and the de novo presence of
augmented nascently synthesized CREB in the distal
sciatic nerve. 2) Disruption of axonal transport prevents
the development of mechanical hypersensitivity and hyper-
algesic priming and prevents increased BDNF expression in
the DRG. 3) Employment of i.t. delivered, CRE decoy oligo-
nucleotides demonstrates that the IL-6-dependent change
in BDNF expression and nociceptive plasticity are select-
ively dependent on CREB within the DRG. Hence, these
findings demonstrate a novel mechanism linking locally
generated signals in the form of the nascent synthesis of a
transcription factor within the peripheral axons of sensory
neurons to remote molecular effects within the cell bodies
that manifest as altered mechanical hypersensitivity and
hyperalgesic priming.
BDNF is well recognized as an important player in
pain sensitization [14,37-39]. Previous studies have
demonstrated that nociceptor-specific knockout of BDNF
leads to a loss of pain sensitization across inflammatory
pain models [38]. Moreover, hindpaw inflammation, hind-
paw treatment with NGF [40] or DRG neuron treatment
in vitro with NGF [41] increases BDNF mRNA expression.
BDNF mRNA is heavily alternatively spliced with 8 possible
5’ untranslated region (UTR) exons spliced to exon 9
which contains the coding sequence. Inflammation in-
creases expression of several exons but the effect is
most robust for exon 1 [41], which is known to respond
to CREB-dependent promoters [17]. Here we observed
an increase in BDNF protein in DRG after hindpaw IL-6
treatment that was dependent on retrograde transport via
the sciatic nerve and that was blocked by i.t. treatment
with CRE decoy oligonucleotides. A possible alternative
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CREB signaling in the dorsal horn of the spinal cord.
Our finding that CRE decoy treatment fails to alleviate
i.t. BDNF-induced mechanical hypersensitivity argues
against a dorsal horn mediated effect pointing to a
DRG-dependent mechanism. We have previously dem-
onstrated a key role for BDNF in the initiation and
maintenance of IL-6-induced hyperalgesic priming
[14,42]. We have also shown a critical role for local
translation in the initiation but not maintenance of IL-
6-induced hyperalgesic priming [6]. Several other studies
have demonstrated similar links between translation control
in DRG neurons and hyperalgesic priming [43-45]. Our
present findings present a possible unification between
these two mechanisms in the form of locally translated
CREB at the time of IL-6 injection linking the initiation and
maintenance of hyperalgesic priming to CRE-dependent
changes in BDNF expression in the DRG. Future studies
will be needed to evaluate the time course of altered BDNF
expression in hyperalgesic priming and whether BDNF
dependency during the maintenance phase requires
nociceptor-derived BDNF or if it originates from other
cells, such as microglia [46-48].
Our results are consistent with a previous study linking
axonal translation of CREB in embryonic DRG neurons to
NGF-induced survival [15]. This study demonstrated the
presence of CREB mRNA in DRG axons and induction of
local CREB translation upon NGF exposure. This nascently
synthesized CREB then undergoes retrograde transport and
influences CRE-dependent transcription in sensory neuron
nuclei. Interestingly, this retrograde transport of axonally
synthesized CREB was required to account for nuclear
accumulation of phosphorylated CREB despite the un-
interrupted presence of retrograde signaling endosomes.
This suggests that local translation, not retrograde endo-
somal signaling, constitutes the necessary machinery for
CRE-dependent changes in transcription via axonal signal-
ing. In development this locally synthesized, retrograde
signal is important for NGF-dependent survival of sensory
neurons [15]. In adulthood our results suggest that this
same mechanism is used to link local insult to changes
in nociceptive sensitivity potentially contributing to the
development of a chronic pain state. Although axonal
CREB transcripts have been observed in DRG neurons
[32], similar studies in sympathetic neurons have failed
to detect axonal CREB transcripts [49]. At this point it is
not clear if axonal mRNA sorting for CREB transcripts is
an exclusive feature of sensory axons or if sympathetic
axons are an exception. CREB is a critical mediator of
neuronal plasticity in Aplysia californica [1,50], an or-
ganism where axon crush creates hyperexcitability in a
manner reminiscent of observations in neuropathic
pain models and patients [1,4,8]. Interestingly, this ef-
fect is mediated by local translation [4] and involvesretrograde transport of an unidentified signaling protein
[8]. Hence, the mechanism we describe here has striking
similarity to sensory neuron plasticity in this phylogen-
etically distinct organism and suggests an evolutionarily
conserved mechanism of nociceptive plasticity.
The time course of effects noted in this study deserves
comment in relation to measurements of axonal trans-
port. We estimate the distance between the axonal ter-
minals in the hindpaw of mice used in this study to the
DRG cell body at ~ 45 mm. At the upper end of estima-
tions for retrograde transport it would take ~ 2.5 hrs for
axonally synthesized CREB to reach the DRG nucleus
[51,52]. A previous study in embryonic DRG neurons in
culture observed retrograde transport rates of ~ 8-9 mm/hr
for axonally synthesized CREB labeled with the photoacti-
vatable florescent probe Dendra [15]. We observed robustly
increased nascently synthesized CREB (AHA-labelled) in
the distal sciatic nerve 2 hrs following intraplantar injection
of IL-6. Moreover, we noted an increase in BDNF pro-
tein in the DRG, which was reversed by either blockade
of retrograde transport or by CRE DNA decoy treatment
[18-20], within 3 hrs of IL-6 treatment. These effects are
within the time frame permissible from previous measures
of retrograde transport [51,52] but are slightly slower
than observations made with photactivatable CREB in
embryonic DRG neurons in vitro [15]. A very recent
study indicated that prior injury can increase antero-
grade and retrograde transport rates in DRG neurons
in vivo and in vitro [53]. While this study used prior
nerve crush as the conditioning stimulus, it is interesting
to speculate that inflammatory stimuli, such as IL-6, may
be able to induce plasticity in axonal transport rates.
There are several caveats to our work that should be
addressed. First, the i.t. approach to the CRE DNA decoy
experiment can be mediated either by an effect on DRG
neurons or spinal cord neurons. CREB has been linked
to pain plasticity at both of these locations. As mentioned
above, BNDF given i.t. at the same time as the CRE DNA
decoy treatment failed to modulate BDNF-induced pain
plasticity. This is despite the previous demonstration
that BDNF induces CREB phosphorylation in dorsal horn
neurons [29]. Hence, we favor an interpretation of our
findings wherein CRE DNA decoy treatment is disrupting
CREB-mediated actions in DRG neurons that are linked
to changes in BDNF expression. We favor a role for
retrograde transport of CREB in this effect as blocking
retrograde transport attenuated the induction of BDNF
in the DRG, however, it is formally possible that this
effect is mediated by retrograde signaling endosomes
that stimulate CREB activity in the DRG. Ultimately,
specific knockdown of axonal CREB mRNA will be needed
to provide definitive proof for this model. Second, the
compounds used here to disrupt axonal transport have
influences on other cells. We cannot completely exclude
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within the nerve in response to IL-6 treatment, however,
such an effect seems unlikely given that IL-6 treatment
itself does not cause any noticeable swelling or flare at
the site of injection. We can exclude a potential sys-
temic effect of these compounds based on experiments
where they were injected into the contralateral leg. It is
also not likely that these transport inhibitors interfere
with nerve conduction as ciliobrevin D had no effect on
capsaicin-induced flinching while this was completely
blocked by lidocaine. Finally, our interpretation of pro-
tein localization of CREB and AHA-incorporated CREB
in the distal sciatic nerve after IL-6 injection is consist-
ent with retrograde transport, however, we cannot com-
pletely rule out a possible contribution of other cells.
Having said this, the sciatic nerve was taken 2 cm from
the site of AHA injection and it is unlikely that sufficient
AHA would travel this distance and incorporate into
CREB in sufficient levels for detection using the methods
employed here. Moreover, even if this contributed to
our observations, such a local effect is completely in-
compatible with our findings linking retrograde transport
and CREB-mediated effects in the DRG to behavioral re-
sponses induced by IL-6. Therefore, despite these caveats,
we propose that the current evidence favors our model
and excludes other alternatives.
We have demonstrated a novel mechanism of nocicep-
tive plasticity linking local translation to changes in gene
expression in the distal DRG. Translation control in DRG
neurons has emerged as an important mechanism of pain
plasticity [5,7,54] but, to our knowledge, no studies have
definitively linked a specific locally translated protein
to functional changes in the nociceptive system. CREB,
an evolutionarily conserved gene controlling neural plasti-




Male ICR mice (Harlan, 20-25 g) were used. All animal
procedures were approved by the Institutional Animal
Care and Use Committee of The University of Arizona
and were in accordance with International Association
for the Study of Pain and National Institutes of Health
Animal Care guidelines. Animals were placed in acrylic
boxes with wire mesh floors and allowed to habituate for
1 hour prior to all behavioral testing. The experimenter
making measurements was always blinded to the experi-
mental conditions. IL-6 (0.1 ng) was injected into the
plantar surface of the left hindpaw in a volume of 25 μl.
BDNF was injected intrathecally (i.t.) in a volume of 5 μl.
Popliteal fossa injections were done immediately after
intraplantar (i.pl.) injections under brief (<3 min) iso-
flurane anesthesia in a volume of 50 μl. The exceptionwas i.pl. capsaicin experiments where the popliteal fossa
injection was done 5-10 min prior to the capsaicin injec-
tion. For i.t. treatments compounds were injected immedi-
ately after i.pl. injections under brief (<3 min) isoflurane
anesthesia in a volume of 5 μl. PGE2 (100 ng) was injected
i.pl. on day 6 or later in a volume of 25 μl. Mechanical
testing was done using the up-down method at time
points indicated in the text. Nocifensive behavior induced
by capsaicin injection was observed over 15 min in mech-
anical testing boxes following habituation of the animals.
Primary neuronal cultures
DRG from ICR mice were excised aseptically and placed in
Hank's Buffered Salt Solution (HBSS, Invitrogen, Grand
Island, NY) on ice. The ganglia were dissociated enzy-
matically with collagenase A (1 mg/ml, 25 min, Roche,
Indianapolis, IN) and collagenase D (1 mg/ml, Roche,
Indianapolis, IN) with papain (30 units/ml) for 20 min at
37°C. To eliminate debris, 70 μm (BD Biosciences, San Jose,
CA) cell strainers were used. The dissociated cells were re-
suspended in DMEM/F12 (Invitrogen, Grand Island, NY)
containing 1X pen-strep (Invitrogen, Grand Island, NY),
1X GlutaMax, 3 μg/ml 5-FDU (Sigma, St. Louis, MO),
7 μg/ml uridine (Sigma, St. Louis, MO) and 10% fetal
bovine serum (Thermo Hyclone, Rockford, IL). The cells
were plated in 6-well plates (BD Biosciences) and incubated
at 37°C in a humidified 95% air/5%CO2 incubator. On day
5 the cells were washed in DMEM/F12 media for 30 min
followed by treatment with escalating doses of IL-6 for
15 minutes.
Nascent CREB synthesis assay
Azidohomoalanine (AHA) is a methionine analogue that
cells can incorporate into nascentlly synthesized proteins.
The left paws of ICR mice were injected with vehicle or
IL-6 (0.1 ng) along with AHA (300 ng, Life technologies)
in 25 μl sterile phosphate buffered saline (PBS). After
15 min or 2 hrs sciatic nerves, taken 2 cm from the in-
jection site, were harvested. Protein was extracted from
the nerves by ultrasonication, centrifugation at 20000 × g
for 15 min and collection of the supernatant. Equal
amount of protein was used to immunoprecipitate
CREB by incubating the supernatant with 1:50 mouse
anti-CREB antibody conjugated to Sepharose beads
(cat # 3955, Cell Signalling, Danvers, MA) overnight at
4°C. This was followed by centrifugation to precipitate
the beads. The pelleted beads were suspended in Tris-SDS
buffer (1% SDS and 50 mM Tris-HCl, pH 8.0), centrifuged
and the supernatant was collected. At this stage, the super-
natant contains the immunoprecipitated CREB where the
nascently synthesized form would have incorporated
AHA. AHA was biotinylated using Click-it Protein
Analysis Detection Kit (Life technologies, Grand Island,
NY) according to the manufacturer’s instructions. The
Melemedjian et al. Molecular Pain 2014, 10:45 Page 9 of 10
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Western blotting.
Western blotting
Protein was extracted from the cells and tissue in lysis
buffer (50 mM Tris HCl, 1% Triton X-100, 150 mM NaCl,
and 1 mM EDTA at pH 7.4) containing protease and
phosphatase inhibitor mixtures (Sigma, St. Louis, MO)
with an ultrasonicator on ice, and cleared of cellular debris
and nuclei by centrifugation at 14,000 RCF for 15 min at
4°C. Fifteen micrograms of protein per well were loaded
and separated by standard 7.5% or 10% SDS-PAGE.
Proteins were transferred to Immobilon-P membranes
(Millipore, Billerica, MA) and then blocked with 5% dry
milk for 3 h at room temperature. The blots were incubated
with primary antibody overnight at 4°C and detected the
following day with donkey anti-rabbit antibody conjugated
to horseradish peroxidase (Jackson Immunoresearch, West
Grove, PA). Signal was detected by ECL on chemilumines-
cent films. Densitometric analyses were performed with
Image J software (NIH, Bethesda, MD).
Drugs and primary antibodies
The anti-CREB rabbit antibodies (cat# 9197) were obtained
from Cell Signaling (Danvers, MA). The BDNF antibody
was from Sigma (cat# AV41970, St. Louis, MO) and βIII-
Tubulin was from Promega (cat# G7121, Madison,
WI). The CRE concensus (cat# sc-2504) and mutant
(cat# sc-2517) oligonucleotides were from Santa Cruz
Biotechnologies (Santa Cruz, CA). Human recombinant
IL-6 and BDNF were from R&D Systems. Colchicine and
nocodazole were from Tocris Bioscience; Ciliobrevin D
was from EMD Millipore and PGE2 was from Cayman
Chemical Company. Capsaicin and lidocaine were from
Sigma Aldrich. Stock solutions for colchicine, nocodazole
and ciliobrevin D were made in cell culture grade 100%
DMSO. BDNF and IL-6 stock solution was made in sterile
PBS containing 0.1% BSA and TrkB/Fc stock solution was
made in sterile PBS. Capsaicin and PGE2 stock solutions
were made in 100% ethanol. Lidocaine stock solutions
were made in sterile saline. All drugs except were diluted
to final concentrations in sterile PBS for injection.
Statistical analysis and data presentation
Data are shown as means and the standard error of the
mean (±SEM) of n = 8 independent cell culture wells,
n = 6 tissue samples for in vivo Western blotting, and
immunoprecipitation or n = 6 independent animals for
behavioral studies. Graph plotting and statistical analysis
used GraphPad Prism Version 5.03 (Graph Pad Software,
Inc. San Diego, CA, USA). Statistical evaluation was
performed by one- or two-way analysis of variance
(ANOVA), followed, where appropriate, by Dunnet post-
hoc analysis for behavioral and Western blot data. Whereonly two comparisons were made (Figure 1B and C)
student’s t-test was used. The a priori level of signifi-
cance was considered to be p < 0.05.
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